TCRX logo

TSCAN THERAPEUTICS INC

TCRXNASDAQ
πŸ† #4766 by market capUS Equity
$0.14β–² $0.00 (+1.99%)
Market closed Β· at close
πŸ””
Track TCRX
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 2.0%
7dβ–Ό 10.9%
14dβ–Ό 23.9%
30dβ–Ό 28.8%
ytdβ–Ό 85.6%
1yβ–Ό 85.0%
🏦Market Cap
$10M
Small Cap
πŸ“ˆRevenue Growth (YoY)
2.1%
Slowing
πŸ“ŠGross Margin
β€”
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
1.4x
Cheap
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$0.14 – $0.15
52-Week Range
$0.14 – $1.47
Volume (shares)
2,870
Avg Volume (shares)
β€”
Shares Outstanding
67.8M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$10M
Last Q Revenue
β€”
P/E Ratio
β€”
P/S Ratio
1.4x
EPS (TTM)
$-0.91
Dividend Yield
β€”
TCRX logo

TSCAN THERAPEUTICS INC

TCRX
Financial Trends

Financial history unavailable.

StockOtter Β· stockotter.space

About TSCAN THERAPEUTICS INC

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.